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Abstract
Background: Oral misoprostol, administered by trained health-workers is effective and safe for preventing postpartum
haemorrhage (PPH). There is interest in expanding administration of misoprostol by non-health workers, including
task-shifting to pregnant women themselves. However, the use of misoprostol for preventing PPH in home-births
remains controversial, due to the limited evidence to support self-administration or leaving it in the hands of
non-health workers. This study aimed to determine if antenatally distributing misoprostol to pregnant women
to self-administer at home birth reduces PPH.
Methods: Between February 2013 and March 2014, we conducted a stepped-wedge cluster-randomized trial
in six health facilities in Central Uganda. Women at 28+ weeks of gestation attending antenatal care were
eligible. Women in the control-arm received the standard-of-care; while the intervention-arm were offered 600mcg of
misoprostol to swallow immediately after birth of baby, when oxytocin was not available. The primary outcome (PPH)
was a drop in postpartum maternal haemoglobin (Hb) by ≥ 2g/dl, lower than the prenatal Hb. Analysis was by
intention-to-treat at the cluster level and we used a paired t-tests to assess whether the mean difference between the
control and intervention groups was statistically significant.
Results: 97 % (2466/2545) of eligible women consented to participate; 1430 and 1036 in the control and intervention
arms respectively. Two thousand fifty-seven of the participants were successfully followed up and 271 (13.2 %)
delivered outside a health facility. There was no significant difference between the study group in number of
women who received a uterotonic at birth (control 80.4 % vs intervention 91.4 %, mean difference = -11.0 %, 95 %
confidence interval [CI] -25.7 % to 3.6 %, p = 0.11). No woman took misoprostol before their baby’s birth. Shivering
and fever were 14.9 % in the control arm compared to 22.2 % in the intervention arm (mean difference = -7.2 %,
95 % CI -11.1 % to -3.7 %), p = 0.005). There was a slight, but non-significant, reduction in the percentage of women
with Hb drop ≥ 2g/dl from 18.5% in the control arm to 11.4 % in the intervention arm (mean difference = 7.1 %, 95 %
CI -3.1 % to 17.3 %, p = 0.14). Similarly, there was no significant difference between the groups in the primary outcome
in the women who delivered at home (control 9.6 % vs intervention 14.5 %, mean difference -4.9; 95 % CI -12.7
to 2.9), p = 0.17).
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Conclusion: This study was unable to detect a significant reduction in PPH following the antenatal distribution
of misoprostol.
The study was registered with Pan-African Clinical Trials Network (PACTR201303000459148, on 19/11/2012).
Keywords: Acceptability, Antenatal distribution, Home births, Misoprostol, Postpartum haemorrhage, Safety,
Stepped-wedge cluster trial
Background
Globally, maternal deaths have declined by 45 % from an
estimated 543,000 maternal deaths in 1990, to 289,000 in
2013 [1]. However, this observed progress is stalled in
sub-Saharan Africa, which now contributes 62 % of all ma-
ternal deaths [1]. Haemorrhage is the leading cause of ma-
ternal death in sub-Saharan Africa, accounting for an
estimated 25 % of deaths [2], and postpartum haemor-
rhage (PPH) defined as bleeding after childbirth of 500
mls or more contributes two-thirds of these [2]. PPH can
be prevented by using a uterotonic immediately after the
birth of the baby, and this intervention is recommended
for all women [3]. The preferred uterotonic is oxytocin
[4], which is available in injectable form and requires re-
frigeration, making it impractical in settings where births
still occur at home under the care of unskilled birth atten-
dants, or where refrigeration is not possible. Misoprostol,
a prostaglandin E1 analogue that induces strong uterine
contractions, is an alternative [5, 6] that is cheap, heat
stable, and has a long shelf-life. While it is not as effective
as oxytocin [7], there is health facility and community evi-
dence to recommend health workers giving 600 micro-
grams of misoprostol orally or sublingually after birth of
the baby, but before delivery of the placenta, to prevent
PPH, when oxytocin is not available [8–12]. There is also
increasing evidence to support the safety of community
distribution of misoprostol through traditional birth atten-
dants and community health workers, which is a low-cost
strategy [13–17]. In view of the emerging evidence, the
World Health Organization (WHO) PPH prevention
guidelines recommend using lay community health
workers to administer misoprostol for PPH prevention
when oxytocin is not available [4]. However, because of
the low quality of evidence on the effectiveness of self-
administered misoprostol use in home births [18], the
WHO and maternal health experts did not recommend
antenatal distribution of misoprostol to women to self-
administer at birth. Rather they recommended more re-
search at the community-level to investigate the effect of
antenatal distribution of misoprostol to pregnant women
to self-administer in third stage of labour in settings or sit-
uations where oxytocin use is not feasible [4, 19, 20].
Uganda is among countries categorized by WHO as
‘not on track’ in achieving MDG 5, [1] with a maternal
mortality ratio estimated at 438 per 100,000 live births.
PPH is the leading cause of maternal mortality and is
responsible for 25 % of deaths [21]. Misoprostol was
approved for preventing and treating PPH in Uganda in
2008 administered by health workers. While most (95 %)
women in Uganda receive antenatal care once and
47.6 % having at least four visits, 42 % still deliver at
home [21]. Giving women misoprostol antenatally to
self-administer after home birth would be a good strat-
egy to prevent PPH. However such a strategy is not yet
approved in Uganda. The main concern for policy
makers is whether antenatal distribution of misoprostol
would encourage home delivery, at a time when the
Ministry of Health is promoting health-facility delivery.
The aim of the present study was to assess the effective-
ness and safety of antenatal distribution of misoprostol
to women to self-administer in home births in prevent-
ing PPH.
Methods
Ethical considerations
Ethical approval was obtained from the School of
Medicine Research and Ethics Committee at Makerere
University, Kampala, Uganda, and the Uganda National
Council for Science and Technology. Permission to carry
out the study was obtained from the District Health Office
(DHO) and respective in-charges of the health facilities.
After information and counselling, eligible women pro-
vided written informed consent and received an informa-
tion sheet in either English or Luganda. The study was
registered with the Pan African Clinical Trials Network
(PACTR201303000459148) on 19/11/2012.
Study design and randomization
We employed a stepped-wedge cluster-randomized trial
design [22] because current evidence on misoprostol use
and postpartum haemorrhage would render a placebo-
controlled trial unethical [19, 22–25] and all facilities ul-
timately get the intervention. A cluster was defined as a
health facility catchment area. All health facilities started
as control-arm facilities. Then in a prior-determined
random order, two facilities “crossed over” to become
intervention facilities during each of the subsequent
three steps for a total of four steps (Fig. 1).
Ononge et al. BMC Pregnancy and Childbirth  (2015) 15:315 Page 2 of 11
The random sequence for starting the intervention
was determined before the start of the study by using
computer generated number sequence. The principal in-
vestigator implemented the randomization. Each step
lasted for two months, and women were followed up on
3rd to 5th day post delivered. Because of the nature of
the intervention, it was not possible to blind the inter-
vention to the care-givers, research team or study
participants.
Participants and setting
The study participants were recruited from six health fa-
cilities in Mpigi district, Uganda, between February 2013
and March 2014. The majority of people in the district
are of low socioeconomic status, with peasant farming
and fishing as their main economic activities. The dis-
trict health infrastructure consisted of 31 health units
(25 government and 6 non-government). These included
one private hospital, one Health Centre IV, 13 Health
Centre IIIs, and 16 Health Centre IIs. The district re-
corded a skilled birth attendant rate of 30 % (2010–11
District Annual Report), although the national average
was 58 % [21]. We enrolled study participants at the
antenatal clinic of the Health Centre IV and the five
Health Centre IIIs.
Two health facilities held their antenatal clinics from
Monday to Friday, while the other four had two dedi-
cated antenatal-care service days per week. Maternity
services at the Health Centre IIIs were staffed by mid-
wives, while the Health Centre IV had three medical
officers in addition to the 7 midwives, and provided
comprehensive emergency obstetric care. The staff in
the antenatal clinic and delivery wards were involved in
recruiting and following up the women, which allowed
the intervention to be delivered as part of ongoing ma-
ternity care.
Eligibility criteria for clinics and women
Clinics: All the 31 health facilities were screened for eli-
gibility. The eligibility criteria were a) that a minimum
of 50 pregnant women attended antenatal clinic (for the
first time) in the month prior to the start of the study,
and b) that the person in-charge of health facility agreed
for the facility to participate. Of the nine facilities that
registered a minimum of 50 antenatal first-time at-
tendees per month, we excluded three; the hospital be-
cause health-care services are paid for (private hospital);
one health facility because its in-charge declined to par-
ticipate; and another because it was difficult to access
the women after home birth during the wet season due
to seasonal rivers and swamps.
Women: Within the antenatal clinics of participating
health facilities, we included all pregnant women who
were 28 weeks or more of gestation, and who had no plans
to leave the district during pregnancy delivery or in the
immediate postpartum period. We excluded women who
had a planned elective caesarean-section delivery or previ-
ous caesarean section scars.
Recruitment of women
Study staff briefed pregnant women attending the ante-
natal clinic about the study objectives and design of the
study in a group. The key messages to the pregnant
women included: 1. The benefits of delivering at the
health facility, 2. Excessive bleeding after child-birth was
dangerous to a woman’s life, 3. The availability of an ef-
fective drug (oxytocin) to stop excessive bleeding that
can be given by trained health worker at the time of
birth in the health facility. 4. For those willing to partici-
pate, the need to alert the research assistant by tele-
phone when and where the delivery occurred. We
repeated the sessions about the study in every antenatal
clinic throughout the study period (in both control and
intervention phases). After the discussion, we invited
those eligible to participate. Each participant gave a writ-
ten informed consent.
Standard-of-care (control)
At the time of the trial, the standard-of-care was that a
women who delivered at a health facility should receive
oxytocin to prevent PPH, while women who delivered at
home received no uterotonic.
Intervention
Women in the intervention period were given 600 micro-
grams (mcg) of oral misoprostol at enrolment to the study
to self-administer after childbirth if delivery happened out-
side a health facility, or when there was no oxytocin at the
health facility. The three tablets of misoprostol (200 mcg
each for a total of 600mcg) in aluminum foil were pack-
aged in a plastic envelope.
Fig. 1 Stepped-wedge schema for the trial. Six clusters were
enrolled at baseline. The white (non-shaded) cells marked “C”
represent the control period. The gray (shaded) cells marked “I”
represent the intervention period
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Instructions to women given misoprostol
Women were given the following instructions; “1. Not to
take the misoprostol tablets when the baby is still inside
the womb, 2. To swallow all the three tablets immedi-
ately after the birth of the baby, if delivery occurred at
home, or if no oxytocin was given by the health pro-
vider. If she had twins, she was to swallow the tablets
after the birth of second twin. 3. To keep the packaging
of tablets (foil) after swallowing them and to give it to
research assistant when she visits her. 4. To carry along
the study tablets (misoprostol) when going to deliver at
a health facility. Hand the misoprostol tablets to the at-
tending midwife or research assistant if delivery oc-
curred at health facility.”
Training the study team
The research assistants and health facility staff in the
antenatal clinics and delivery wards from the six study
facilities were trained on the protocol for 5 h. This com-
prised of study material and key messages to women
attending antenatal clinic, and was delivered by the prin-
cipal investigator. Weekly supervisory visits by the prin-
cipal investigator followed the initial training and further
training was given as requested or as assessed by the
principal investigator.
Data collection
The study participants were interviewed face-to-face by
a trained research assistant. We used a pre-tested ques-
tionnaire to collect socio-demographic characteristics in-
cluding maternal age, education, marital status, maternal
occupation and religious affiliation. We also inquired
about parity, gestation at first antenatal visit, the use of
prophylactic anti-malarials, transport costs to the health
facility for antenatal care, and delivery plans. We estab-
lished gestational age from the woman’s last normal
menstrual period (LNMP) or ultrasound scan estimation.
In a few cases where we did not have LNMP or an ultra-
sound scan, we used fundal height to approximate the
gestational age [26]. Trained research assistants measured
haemoglobin (Hb) levels at enrolment (during their third
trimester antenatal care visit) and three to five days after
delivery using a portable HemoCueR Hb 301 system. as
described in another part of the study that looked at
haemoglobin status of pregnant women [27].
Follow up of participants
All pregnant women enrolled in the study continued re-
ceiving standard antenatal care at the local health facility.
A sticker identifying them as enrolled study participants
was placed on their hand-held antenatal cards to make it
easier to identify them at repeat antenatal visits or when
they reported in labour. The sticker had three telephone
numbers that the women could call to contact the study
team once they had delivered or if they had any problems
or questions about study. At enrolment, women were ad-
vised to deliver in a health facility as per national guide-
lines. They were also advised to seek care in case they had
excessive bleeding after child birth, the placenta had not
delivered within one hour, or the baby did not cry imme-
diately after birth or developed a fever. The study kept a
log of participants’ names, contact telephone numbers
and the name of the village health worker where they
lived. The study team contacted any woman who had
passed her estimated delivery date to identify if she had
given birth and from where. Midway through the study,
we observed that the names of participants in the log book
were often not what the women were called by the com-
munity members in the village, so we subsequently modi-
fied our procedures to ask participants for the names
(petty names) the community members usually called
them. Research assistants visited the woman either at
home or at the health facility after birth to measure the
haemoglobin and complete postnatal questionnaire. Par-
ticipants were defined as lost-to-follow-up when we were
unable to physically contact them eight weeks after the ex-
pected date of delivery.
Outcome measures
The primary outcome was PPH, defined as a drop in
maternal haemoglobin by 2g/dl or more, lower than the
prenatal Hb [10].
Secondary outcomes were: postpartum anaemia de-
fined as Hb < 11 g/dl when assessed within 7 days and
Hb < 12 g/dl if assessed after the 7th day after childbirth
[28], place of child-birth, use of any uterotonics for pre-
vention of PPH, referral to a health facility after delivery,
blood transfusion and maternal death. We asked the
women about side effects related to misoprostol use,
such as fever (self-report of body feeling hot), chills,
shivering and how they coped with them. Safety was de-
fined as swallowing of the medicine after delivery of the
baby or babies. Specific to the intervention group, we
also assessed the timing of swallowing misoprostol, and
its acceptability to women. We asked the women in the
intervention group to keep the blister package of the mi-
soprostol (used or unused) and hand it to research as-
sistant at home during the follow up visit or to the nurse
at the health facility where the woman delivered.
Sample size
Sample size was calculated taking into account the clus-
tering effect. We assumed a between cluster correlation
coefficient km = 0.2, a minimum of 200 pregnant women
per health facility in each phase (m), and proportion ex-
periencing PPH of 12.0 % [9]. Assuming 80 % power to
detect a difference of 50 % in PPH proportions between
the two groups with a type I error of 5 %, using formula
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for matched cluster trial [29], the study needed six
health facilities in each arm,
Statistical analysis
Analysis was conducted on an intention-to-treat principle,
based on the period (intervention or control) at which
women were enrolled into the study. We compared the
characteristics of women enrolled in the control and the
intervention periods at individual level and these were
summarized as percentages for categorical outcomes, and
means (and standard deviations) for continuous outcomes.
Cluster-level summaries of some women’s characteristics
in the control and intervention periods were computed
and presented as means and standard deviations.
The primary outcome (postpartum Hb ≥ 2g/dl lower
than prenatal Hb) in each arm was expressed as the
mean of the six cluster-level proportions of women who
had PPH measured in each cluster in intervention and
control periods respectively. The effect of the interven-
tion was measured as the difference in the means of pri-
mary outcome of the two groups (with 95 % confidence
interval [CI]). We used paired t-tests to assess whether
the mean difference between the two groups was statisti-
cally different from zero. We also applied a paired t-test
to assess the difference in the means of the secondary
outcomes between the control and intervention groups.
Uterotonic use included a summary statistic of utero-
tonic received at birth and was cross-tabulated with
place of birth. The acceptability of misoprostol as a
number of home births who ingested misoprostol and
were willing to use it next pregnancy or recommend it
to relative. Results were summarized as frequency distri-
bution. Because the study did not have a lag phase, some
of women recruited during the control period delivered
in the intervention period.
Results
Participants flow
All six clusters enrolled contributed to the control and
intervention periods. Two thousand five hundred and
forty-five women who came for antenatal care at the six
health facilities during study period were eligible, and
2466 (97 %) consented to participate. A total of 409
women (17 %) were lost to follow up; 19.9 % in the con-
trol arm and 12.0 % in the intervention arm. Reasons for
lost to follow up included being unable to contact
women as phone contacts were switched off or change
of address. Figure 2 shows the flow of study participants
according to the Consort guidelines extension for
cluster-randomized trials [30].
Baseline characteristics
Table 1 shows the characteristics of the study participants
enrolled in the control and the intervention periods. The
baseline data established that randomization of the clus-
ters to the two study periods were similar for almost all
variables except for a lower prevalence of antenatal an-
aemia and HIV sero-status in women enrolled during the
intervention period. The mean cluster size in control was
more in control than in intervention period.
Of the 2466 women recruited, 2057 (83.4 %) were suc-
cessfully followed up. The median time to follow up was
17 days, ranging from 3 to 96 days postpartum. Among
the women who were successfully followed up, the me-
dian (IQR) time from delivery to postpartum Hb meas-
urement was 9 (4–22) and 7 (4–17) days in the control
and intervention respectively. However 412/1140(36.3 %)
in the control and 377/909 (41.4 %) in the intervention
had the follow up done within 3–5 days.
One thousand seven hundred eighty-six (86.8 %) deliv-
ered at a health facility. One hundred fifty (7.3 %)
women were delivered by caesarean section; 78/1146
(6.8 %) were in control arm while 72/911 (7.9 %) in inter-
vention. Of the 271/2057 (13.2 %) women who delivered
outside health facility, 168 (62.0 %) were assisted by trad-
itional birth attendants, 141 (52 %) by relatives, 14
(5.2 %) were alone and 19 (7.0 %) by their husband. (The
sum is more than 271, some births were attended too by
more than one person.)
Outcomes
Primary outcome
Overall, we measured maternal postpartum Hb in
2049/2057 (99.6 %) women who had a complete follow
up done. Hb drop of ≥ 2g/dl was slightly more in con-
trol than in intervention period (18.5 % vs 11.4 % re-
spectively; risk difference = 7.1%, 95 % CI -3.1 to 17.3,
p = 0.14) Table 2.
Secondary outcomes
More women in the intervention period experienced
fever and shivering (known side effects of misoprostol)
compared to control period. However, there was no
statistical differences between the intervention and con-
trol periods in any of the other secondary outcomes
(postpartum anaemia, uterotonic use and facility births)
Table 2. 5/893 (0.5 %) women in intervention period and
7/1118 (0.6 %) in the control period received blood
transfusion.
Of the home deliveries (271/2057, 13 %), fewer
women in control than intervention arm experienced
Hb drop ≥ 2g/dl drop (9.6 % vs 14.5 % respectively),
however, there was no statistical difference between the
two arms (mean difference -4.5 %; 95 % CI -12.7 to 2.9,
p = 0.17). Two women in each period were transferred
from home to a health facility after child-birth for
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neonatal complications, none of which were related to
misoprostol use.
Uterotonic use: Figure 3 shows the women’s use of
uterotonic by birth place and study group. Over 60 %
women who gave birth outside health facility (home
or traditional birth attendant’s home) in intervention
arm self-administered misoprostol after birth. Among
the women who delivered at a health facility, oxytocin
was the main uterotonic used. However, when we
considered only women who gave birth at the health
facilities (public and private), receiving oxytocin was
less common in intervention than in control period.
This may be due to an unfortunate co-incidence of
stock outs of oxytocin during the intervention period.
Two hundred thirty-four women swallowed misopros-
tol despite delivering at a health facility and the fol-
lowing were reasons cited: facility stock-outs of
injectable oxytocin (16.6 %), lack of syringes for ad-
ministering oxytocin (15.7 %), told by the midwife to
take the misoprostol (23.0 %), persistent bleeding
despite receiving injectable uterotonic (so received
both injectable and misoprostol) (16.6 %). However
24.7 % of women decided to take misoprostol without
a justifiable reason. The private-for-profit health facil-
ities had higher misoprostol use than other types of
facilities. The misoprostol use in private-for-profit in-
creased by 10 fold during the intervention period.
Among the 138 women who received misoprostol and
delivered at home or in a traditional birth attendant’s
home, 90 (65.2 %) used misoprostol (Fig. 3). Of the 48
women who did not swallow the misoprostol, 17
(35.4 %) of them forgot, 10 (20.8 %) misplaced it, 3
(6.3 %) did not have the pills at the time of delivery and
18 (37.5 %) decided not to take it.
Acceptability of misoprostol
Of the 90 women who had home births and swallowed
misoprostol, 85 (94.4 %) would use it in the next birth.
The other five women opted not to have any more preg-
nancies. Eighty-seven (96.7 %) would recommend miso-
prostol to a friend or relative.
Fig. 2 Participants flow diagram of the stepped-wedge, cluster randomized trial: All six facilities started as controls in the first step and two health
facilities crossed over to the intervention arm in each step
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Safety of misoprostol use
Of the 324 women who took misoprostol at birth (either
in a health facility, at home or in a traditional birth at-
tendant’s home), none took it before the baby was born
(Table 3). However, the majority of women took the mi-
soprostol after delivery of placenta, even though in the
enrolment they were advised to take it after the baby is
born but before the placenta was delivered. During study
period, four maternal deaths were registered, and all of
which occurred in control group. The causes of death
were: sickle-cell crisis, PPH after caesarean section with
postoperative haemorrhage, PPH secondary to abruption
placenta, and alleged domestic violence.
Discussion
Antenatal distribution of misoprostol to women showed
non-significant a reduction in the incidence of primary
outcome of Hb drop ≥ 2g/dl at birth (7.1% [95 % CI
-3.1 %, 17.3 %]). However it increased the use of utero-
tonic at birth more especially in private-for-profit health
facilities and at home or at a traditional birth attendant’s
home. Antenatal distribution also increased access to
uterotonics at health facility births at times of oxytocin
or syringe stock-out.
In this study, we found that more women delivered at
a health facility (87 %) than reported in the National
Demographic Health Survey 2011 (58 %) [21], however,
there was no difference between the intervention and
control group in the number of women presenting to
deliver at the health facility. The women in the interven-
tion reported more fever and shivering than women in
control group (7.2 % [95 % CI 3.4 %, 11.1 %]), both com-
mon side effects of misoprostol. Majority of community
births were assisted by traditional birth attendants and
given the small number of women who delivered at
home, there was no statistically significant difference be-
tween the groups in the rate of PPH.
Our study had the following limitations; it was not
possible to mask the participants or the research team,
to the intervention given its nature. Secondly, only
38.5 % of the women were seen within 5 days after birth,
which affects the power of study and may introduce
reporting bias of the primary outcome, however the
mean difference in PPH between the two arms was not
affected when all the women followed were included in
analysis. Thirdly loss to follow-up of 17 % was high,
however characteristics of women at enrollment were
not different from those followed up (data not shown),
and similar in the control and intervention groups. Dif-
ferent levels of loss-to-follow-up in the interventions
(12 %) and control arms (20 %) may have been because
we improved follow-up procedures by identifying petty
names midway thought the study, when most clusters
were intervention clusters. The strengths of the study in-
clude that the stepped-wedge design may increases the
power of the study, since health facilities acted as their
own control [22], and the study allowed us to assess the
intervention in realistic setting.
The women in intervention group experienced lower
PPH than the control group, however there was no stat-
istical difference between the two groups. This is in con-
trast to community placebo randomized trials in India
[9] and Pakistan [23] that showed a reduction of PPH in
women who received misoprostol. The lack of observed
reduction in PPH could have been due to the late follow
up (more than 5 days) of majority of the participants
that may cause inaccuracy in obtaining the true fall in
Hb, knowing that women are subject to the natural
Table 1 Baseline characteristics of the study participants and
clusters (N = 2466)
Variable Control period
N = 1430
Intervention period
N = 1036
Individual level summary
Age in completed years
(mean, sd)
24.6 (±5.7) 24.2 (±5.5)
Below 20 261 (18.3 %) 221 (21.3 %)
20–24 548 (38.3 %) 400 (38.6 %)
25–29 409 (28.6 %) 278 (26.8 %)
30–34 101 (7.1 %) 76 (7.3 %)
≥ 35 111 (7.8 %) 61 (5.9 %)
Parity(mean, sd) 2.1 (2.0) 1.9 (1.9)
Nullipara 372 (26.0 %) 277 (26.7 %)
1 335 (23.4 %) 256 (24.7 %)
2 223 (15.6 %) 194 (18.7 %)
3 179 (12.5 %) 110 (10.6 %)
4 140 (9.8 %) 91 (8.8 %)
5+ 181 (12.7 %) 108 (10.4 %)
Gestational age at enrolment
(mean, sd)
32.4 (3.4) 32.1 (3.3)
Antenatal Hb in g/dl
(mean, sd)
11.40 (1.44) 11.65 (1.28)
Antenatal anaemia
(Hb<11.0 g/dl)a
512 (36.1 %) 279 (27.4 %)
HIV positive 122 (8.5 %) 71 (6.9 %)
Cluster level summary
Cluster size (mean, sd) 238 (166) 173 (169)
Age in years (mean, sd) 24.5 (0.44) 24.5 (0.87)
Years at school (mean, sd) 7.6 (0.60) 7.5 (0.75)
Parity (mean, sd) 2.1 (0.23) 2.0 (0.44)
Antenatal anaemia
(Hb<11.0 g/dl)a (mean, sd)
36.7 (8.1) 30.7 (7.5)
HIV positive (mean, sd) 8.2 (2.0) 6.3 (1.4)
Hb Haemoglobin, HIV Human Immunodeficiency Virus, sd standard deviation
aData on antenatal anaemia available for 1427 women in the control group
and 1019 in the intervention group
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Table 2 Main outcomes measures in control and intervention groups cluster level summaries
Outcome Control group (n=6) Intervention group (n=6) Risk differencec (Control-intervention) (95 % CI) p-value
Primary outcome
PPH Hb diffa ≥2g/dl (sd) 18.5 % (5.9) 11.4 % (8.4) 7.1 % (-3.1 % to 17.3 %) 0.14
PPH Hb diffb ≥2g/dl (sd) 15.0 % (4.3) 11.1 % (3.0) 3.9 % (-1.5 % to 9.3 %) 0.12
Secondary outcomes
Postpartum anaemia (sd) 43.3 % (10.0) 41.3 % (11.0) 2.0 % (-2.4 % to 6.4 %) 0.30
Health facility births (sd) 87.5 % (7.3) 85.4 % (9.3) 2.1 % (-1.4 % to 5.6 %) 0.19
Uterotonic use at birth (sd) 80.4 % (12.6) 91.4 % (7.0) −11.0 % (-25.7 % to 3.6 %) 0.11
Fever & shivering (sd) 14.9 % (3.4) 22.2 % (5.3) −7.2 % (-11.1 % to -3.7 %) 0.005
PPH postpartum haemorrhage, aHb diff=postpartum haemoglobin - antenatal haemoglobin in women followed within 3rd to 5th day; n=412 in control and n=377
in intervention, bHb difference in all women; n=1140 in control and n=909 in intervention, c risk difference at cluster level are in means, sd standard deviation,
CI confidence interval
Fig. 3 Participants’ use of uterotonics by place of delivery and study arm. C = control group, I = intervention group, TBA = traditional birth attendant,
Govt HC = Government Health Centre, PNFP = private not-for-profit, PFP = private-for-profit
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rebound in the postpartum haemoglobin from day 7
after childbirth. The findings of no significant difference
between the groups was possibly due to lower power of
the study. The proportion of women with PPH among
the intervention group was expected to be half lower
than the control group according to the power calcula-
tions, but the results did not support reduction. The lack
of observed reduction in PPH could also have been due
to the a high rates of facility deliveries in both arms
(possibly because this was emphasized during antenatal
care, and in essence was one of the benefits observed
arising from the study). This meant that many women
got an injectable uterotonic, the standard of care in pre-
vention of PPH. While this finding allays the concern of
many policy makers who feared the antenatal distribu-
tion of misoprostol would encourage women to deliver
at home, it made it harder to measure an effect. Our
finding of more women returning to give birth at health
facility supports population data from other studies
reporting increased utilization of health facilities for de-
liveries in programmes implementing advanced distribu-
tion of misoprostol [31]. This means that the education
and counseling to participants that went along with the
distribution of misoprostol on the dangers of PPH,
prompted many women to opt to deliver at the hands of
skilled birth attendant or health facility in fear of com-
plications of bleeding after childbirth.
Antenatally distributed misoprostol to women im-
proved uterotonic use in institutional births. The in-
crease in uterotonic utilization was noted more at
private for profit health facilities. The use of misoprostol
for PPH prevention in the private for profit health facil-
ities increased from 4 % to 46 %. The possible explan-
ation could be that misoprostol carried by the woman
was an inducement for the staff at the private health fa-
cility not to use their stock of uterotonic, reducing the
cost of items used at birth. In addition some of these pri-
vate health facilities have stock outs of injectable utero-
tonic and misoprostol is cheaper for them and it does
not require cold chain. Misoprostol used in addition to
oxytocin in women who had institutional births and got
persistent bleeding is opportunity for use of misoprostol
for treatment of PPH.
Two-thirds (65.2 %) of the women who had home
births and were in intervention group used misoprostol.
This was encouraging, although it is less than the level
of misoprostol use after home births reported in other
settings (87.7 %–99 %) [13–15, 32–34]. The possible ex-
planation for the slightly lower level of use in our study
was that some women perceive bleeding after child birth
as cleansing process and should not be inhibited. In
addition, we gave misoprostol to some of the women as
early as 28 weeks of pregnancy. There is increased
chance to misplace the misoprostol or forget to use it. A
recent review shows that early distribution of misopros-
tol in pregnancy is associated with lower rates of miso-
prostol use [11]. High levels of misoprostol use in home
births is attributed to late pregnancy distribution (more
than 32 weeks) [13, 14, 34] and use of village health
workers as a distribution channel during home visits
[13–15, 32]. So we may need to use the village health
workers as distributors and see if there is a leap in num-
ber using misoprostol. Some studies register high rates
because they use ancillary nurse midwives or TBAs to
administer misoprostol at the time of birth [15, 34]. The
eighteen women who decided not take misoprostol may
have felt that they were not in danger. However, as earl-
ier mentioned, some of these women may have consid-
ered bleeding after childbirth as a cleansing process and
it is good for body. They perceive that stopping the
bleeding process may cause the dirty things to stay in
the body and is responsible for abdominal pains after
childbirth, postpartum infection and later infertility. To
them bleeding after childbirth should not be inhibited.
The underlying belief that blood of childbirth is dirty
has been reported among women in Morocco who also
believe that blood of childbirth is bad and potentially
poisonous inside the body [35].
Our study observed more women in the intervention
phase than the control phase experienced fever and shiv-
ering, both of which are well known and documented
side effects related to misoprostol use [7, 12, 36–38].
Fever and shivering were transient and the majority of
women had symptoms subsiding within 2 h of misopros-
tol use. On the safety of antenatal distribution of miso-
prostol, our study had no incidence of misoprostol
reported as being taken before the birth of the baby
when it might harm the baby or lead to ruptured uterus,
and all the women swallowed misoprostol after birth of
the baby. This result concurs with reviewed literature
that document very low rates (0.06 %) of mistimed ad-
ministration of misoprostol [11] and this further allays
concerns of the policy makers and international health
community about the safety of antenatal distribution of
misoprostol to women to self-administer in home births.
Table 3 Timing of swallowing misoprostol tablet among the
women who took it, by place of delivery
When misoprostol was swallowed Home or TBA’s
place n=90 (%)
Health facility
n=234 (%)
Before baby was born 0 0
After the baby was born but before
the placenta was delivered
32 (35.6 %) 74 (31.6 %)
After the placenta was delivered but
within an hour of birth
58 (64.4 %) 159 (68.0 %)
More than 1 h after delivery 0 1 (0.4 %)
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However, a substantial proportion swallowed it after the
placenta was delivered, which may not be within one mi-
nute after delivery of baby; a recommendation for active
management of third stage of labour [39]. Similar findings
by Smith et al and Weeks et al have showed that despite in-
structions of swallowing the tablets before birth of placenta,
some swallow the tablets after placenta is delivered [14, 40].
The late administration of misoprostol may cause delay in
onset of action and may ultimately contribute to the lack of
effect on PPH. Though it is not well-established or known
whether misoprostol administered after placental delivery
significantly affects its uterotonic effect in reducing blood
loss, we recommend a focused knowledge session and
counseling at time the woman is offered misoprostol. In
addition, a written pamphlet with instructions on how to
swallow and the use of reminder messages given to women
after distribution of the misoprostol either by phone “short
text messages” or in subsequent visits would enhance re-
membrance of instructions on when to take the tablets.
Four maternal deaths that occurred during the study
period, all of them from the control period and were not
related to use of misoprostol or other uterotonics. The
death of the woman who had PPH secondary to abrup-
tion placentae could have been averted if the health fa-
cility had capacity and skill to adequately treat a PPH.
The facility had only intravenous fluids, oxytocin and
misoprostol, which she received, but the inability of the
health facility to carry out blood transfusion, or other
temporizing measures like using balloon tamponade or
anti-shock garments made the woman more vulnerable
to death once she got a PPH [41, 42]. Acceptability of
misoprostol was high with 94 % of women who gave
birth at home and took misoprostol agreed or were will-
ing to take it in the next pregnancy. They were ready to
recommend it to a friend or relative.
Conclusions
This study was unable to detect a significant reduction in
Hb drops following the antenatal distribution of misopros-
tol. However, antenatal distribution of misoprostol to
women, increased uterotonic use at birth and return to
deliver at health facility. The safety of self-administration
of misoprostol with close supervision and monitoring was
demonstrated in this study. This study supports a poten-
tial strategy of antenatal distribution of misoprostol to
women to self-administer for prevention of PPH, though
more attention should be paid to educating women on
when to take it in relation to delivery of the placenta.
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